Product Name
BMPR1A, siRNA
Full Product Name
BMPR1A siRNA (Rat)
Product Synonym Names
Bone morphogenetic protein receptor type-1A; BMP type-1A receptor; BMPR-1A; Activin receptor-like kinase 3; ALK-3; Bone morphogenetic protein 4 receptor; CD antigen CD292
Product Gene Name
BMPR1A sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q78EA7
Specificity
BMPR1A siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat BMPR1A gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of BMPR1A sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
BMPR1A sirna
siRNA to inhibit BMPR1A expression using RNA interference
Applications Tested/Suitable for BMPR1A sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for BMPR1A. It may not necessarily be applicable to this product.
NCBI Accession #
NP_110476.1
[Other Products]
NCBI GenBank Nucleotide #
NM_030849.1
[Other Products]
UniProt Primary Accession #
Q78EA7
[Other Products]
UniProt Secondary Accession #
Q64308[Other Products]
UniProt Related Accession #
Q78EA7[Other Products]
Molecular Weight
59,994 Da
NCBI Official Full Name
bone morphogenetic protein receptor type-1A
NCBI Official Synonym Full Names
bone morphogenetic protein receptor, type IA
NCBI Official Symbol
Bmpr1a??[Similar Products]
NCBI Protein Information
bone morphogenetic protein receptor type-1A
UniProt Protein Name
Bone morphogenetic protein receptor type-1A
UniProt Synonym Protein Names
Activin receptor-like kinase 3; ALK-3; Bone morphogenetic protein 4 receptor; CD_antigen: CD292
Protein Family
Bone morphogenetic protein receptor
UniProt Gene Name
Bmpr1a??[Similar Products]
UniProt Synonym Gene Names
BMP type-1A receptor; BMPR-1A; ALK-3??[Similar Products]
UniProt Entry Name
BMR1A_RAT
NCBI Summary for BMPR1A
may act as a serine/threonine kinase receptor; may mediate bone morphogenetic protein-induced bone formation [RGD, Feb 2006]
UniProt Comments for BMPR1A
BMPR1A: a serine/threonine-protein kinase receptor for Bone morphogenetic protein-2 and -4 (BMP-2 and BMP-4). Defects in BMPR1A are a cause of juvenile polyposis syndrome (JPS) and Cowden disease (CD), a cancer syndrome characterized by multiple hamartomas and by a high risk for breast, thyroid and endometriel cancers.
Protein type: EC 2.7.11.30; Protein kinase, TKL; Protein kinase, Ser/Thr (receptor); Membrane protein, integral; Kinase, protein; TKL group; STKR family; Type1 subfamily
Cellular Component: cell soma; dendrite; plasma membrane; integral to membrane; caveola
Molecular Function: transforming growth factor beta receptor activity; protein serine/threonine kinase activity; protein homodimerization activity; metal ion binding; SMAD binding; ATP binding; receptor signaling protein serine/threonine kinase activity
Biological Process: paraxial mesoderm development; transcription from RNA polymerase II promoter; heart morphogenesis; neural plate mediolateral pattern formation; hindlimb morphogenesis; developmental growth; neural crest cell development; positive regulation of transcription, DNA-dependent; heart development; paraxial mesoderm structural organization; mesendoderm development; dorsal/ventral axis specification; palate development; protein amino acid phosphorylation; negative regulation of neurogenesis; anterior/posterior pattern formation; BMP signaling pathway; positive regulation of mesenchymal cell proliferation; ectoderm development; embryonic morphogenesis; cell differentiation; nervous system development; Mullerian duct regression; somitogenesis; regulation of endothelial cell proliferation; in utero embryonic development; stem cell maintenance; lateral mesoderm development; positive regulation of bone mineralization; pattern specification process; regulation of endothelial cell differentiation; odontogenesis of dentine-containing teeth; positive regulation of osteoblast differentiation; dorsal/ventral pattern formation; mesoderm formation; pituitary gland development; cartilage development; embryonic organ development; immune response; embryonic digit morphogenesis; regulation of lateral mesodermal cell fate specification; positive regulation of epithelial cell proliferation; endoderm development; lung development
Research Articles on BMPR1A
1. Expression of BMPR IA increases significantly in the astrocytes and activated microglia cells in rats after contusive spinal cord injury.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
